Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Revenue

In the year 2025, Innovent Biologics had annual revenue of 13.04B CNY with 38.42% growth. Innovent Biologics had revenue of 7.09B in the half year ending December 31, 2025, with 102.26% growth.

• Revenue: 13.04B CNY
• Revenue Growth: +38.42%
• P/S Ratio: 10.40
• Revenue / Employee: 1.74M CNY
• Employees: 7,502
• Market Cap: 150.94B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	13.04B	3.62B	38.42%
Dec 31, 2024	9.42B	3.22B	51.82%
Dec 31, 2023	6.21B	1.65B	36.21%
Dec 31, 2022	4.56B	286.65M	6.71%
Dec 31, 2021	4.27B	425.91M	11.08%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 28, 2026

Data Sources Report a data error